Ryan Gentzler, MD· @ryangentzler · X·· 14 小时前评分70
正文 · 原文
Excited to see the highly anticipated DeLLphi-305 at #ESMO26. First line maintenance tarlatamab + durvalumab improves PFS and OS.
Updated label for outpt monitoring hopefully make this more accessible for all #SCLC patients.
The next frontier: Limited Stage consolidation
46 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Ryan Gentzler, MD · x.com